Genomic Vision announces the approval of all resolutions supported by the Executive Committee by the General Assembly

Bagneux, France – (BUSINESS WIRE) – Regulatory News:

Genome vision (FR0011799907 – GV, PEA-PME target)Biotechnology companies developing tools and services dedicated to the analysis and control of advanced glycation end will inform shareholders that the Extraordinary General Assembly (AGE) held today has been successfully deliberated.

Existence of agent For this It is now possible to secure the required quorum for the purpose of representing shareholders who are not attending and not attending the meeting. Adhooks have two-thirds of the votes in favor and one-third of the votes against the default shareholder’s shares in order to participate in “neutral” deliberations in terms of voting rights. Exercised in. Many.

EGM has adopted all proposed resolutions except 21.th A resolution rejected in accordance with the recommendations of the Management Committee.

The meeting specifically approved the establishment of a new funding line with Winance of up to € 28.8 million (nominal value € 30 million) through the issuance of reservations for OCABSA. This issue was addressed in a prospectus approved by Autorité des marchés financiers (AMF) on May 20, 2022 with approval number 22-170 consisting of a universal registration document submitted on April 14, 2022 with number D.22-0293. It was the subject. , 80/84 Rue des Meuniers, 92220, amendments to the Universal Registration Document for Securities Notes and Summary, filed May 20, 2022 at number D.22-0293-A01. Bagneux), our website (www.genomicvision.com) and the AMF website (www.amf-france.org). This approval by the AMF should not be seen as a favorable opinion regarding the quality of the issuer and the financial securities subject to the prospectus. Investors are requested to evaluate the adequacy of their investment in the relevant financial securities by themselves.

The minutes of the extraordinary general meeting of shareholders on May 23, 2022 will be available within the statutory deadline in the Investor / General Meeting section of our website.

About Genome Vision

GENOMIC VISION is a biotechnology company that develops products and services that specialize in the analysis of genomic modifications (structural and functional) and the control of the quality and safety of these modifications, especially in genomic editing and bioproduction processes. is. .. Based on DNA combing technology and artificial intelligence, GENOMICVISION’s unique tools provide the robust quantitative measurements needed for reliable characterization of DNA changes in the genome. These tools are used for early detection of cancer and diagnosis of genetic disorders, especially to monitor DNA replication in cancer cells. Based in Bagneux, Paris, the company has approximately 30 employees. GENOMIC VISION is listed on Compartment C (Euronext: GV – ISIN: FR0011799907), the regulated market for Euronext in Paris.

www.genomicvision.com

Index member CAC® Small and medium When CAC® All can be traded

caveat

This press release contains implicit or explicit forward-looking statements related to Genomic Vision and its activities. Genomic Vision believes that these forward-looking statements are based on reasonable assumptions. However, we guarantee the achievement of the forecasts set forth in these forward-looking statements affected by risk, including those described in the Risk Factors section of the Universal Registration document submitted to Autorité des Marchés Financiers. You can’t. AMF), April 14, 2022, with registration number D. 22-0293, updated with amendments submitted to Autorité des Marchés Financiers (AMF) on May 20, 2022, with number D. 22-0293-A01. .. Changes in the company’s website (www.genomicvision.com) and the economic conditions, financial markets, and markets in which GenomicVision resides. The forward-looking statements contained in this press release are also exposed to risks unknown to Genomic Vision or risks that Genomic Vision does not consider materiality at this time. Realizing all or part of these risks will result in the actual results, financial position, performance or performance of Genomic Vision being significantly different from the results, financial condition, performance or performance shown in these forward-looking statements. There is a possibility.

This press release and the information contained therein do not constitute an offer or invitation to sell or subscribe to Genomic Vision shares, or an order or invitation to purchase or subscribe to Genomic Vision shares, and shall be construed in any country. It’s not a thing either. Distribution of this press release in certain countries may violate the legal provisions in force. Therefore, anyone in possession of a press release must notify themselves of regional restrictions and comply with them.

contact address

Genome vision
Dominique Remy-Lenou

Chairman of the Management Committee

like that. : +33 1 49 08 07 51

[email protected]

Ulysses Communication
Press related

Bruno Arabian

like that. : +33 1 42 68 29 70

[email protected]

NewCap
Public relations activities for investors

& Strategic communication

like that. : +33 1 44 71 94 94

[email protected]